Andrew Hopkins
Chief Executive Officer at Kinetic Discovery Ltd.
Net worth: 76 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Elizabeth Crain | F | 59 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 3 years |
Ben Taylor | M | 46 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
David Hallett | M | 54 | 4 years | |
Mario Polywka | M | 61 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 7 years |
C. Nicholson | M | 68 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
Joanne Xu | F | 46 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 3 years |
Chris Thomas | M | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 5 years |
Amanda Galgay | F | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 2 years |
Garry Pairaudeau | M | 58 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
Robert Ghenchev | M | 41 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
Sara Blum Sherman | F | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 3 years |
Iva Navratilova | M | - |
Kinetic Discovery Ltd.
Kinetic Discovery Ltd. Pharmaceuticals: MajorHealth Technology Kinetic Discovery Ltd. engages in the provision of drug discovery services. It offers full kinetic characterization, compound screening, fragment based screening, membrane protein analysis, active concentration determination, epitope mapping, promiscuous binding identification, and consultancy and assay development. The company was founded by Iva Navratilova and Andrew L. Hopkins and is headquartered in Dundee, the United Kingdom. | - |
Mark Basil Swindells | M | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | - |
John Overington | M | - | 3 years | |
Richard Henry Cheetham Bickerton | M | 80 | 3 years | |
Dave Hallett | M | 54 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
Caroline Rowland | F | - | 2 years | |
Robert Anthony Kennedy | M | 54 |
University Of Dundee
| 17 years |
Dan Ireland | M | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | - |
Michael Krams | M | 63 | 2 years | |
Eileen Jennings-Brown | F | - | 2 years | |
Franziska Michor | M | 41 | 1 years | |
Parker Moss | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Georgy Egorov | M | 48 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 2 years |
Alexander Snow | M | 54 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | - |
Xia Milly Chen | F | - | 4 years | |
Okeowo Gbolade | M | - |
University Of Dundee
| 1 years |
Sarah Manderson | F | - |
University Of Dundee
| 2 years |
Omar Omar | M | - |
University Of Dundee
| 4 years |
Richard Cox | M | - | - | |
Andrew Bowen | M | - |
University Of Dundee
| 4 years |
Adrian Schreyer | M | - | 4 years | |
Clare Stokes | F | - |
University Of Dundee
| 3 years |
Ben Ashwell-Fryer | M | - | 4 years | |
Mark Eccleston | M | 42 |
University Of Dundee
| 2 years |
Adam Watson | M | - |
University Of Dundee
| 4 years |
Luis Renato Sánchez Torino | M | - |
University Of Dundee
| 3 years |
Xiao Dong Luo | M | 37 |
University Of Dundee
| 1 years |
Zhanibek Saurbek | M | - |
University Of Dundee
| 3 years |
Kate Suinner | F | - |
University Of Dundee
| 3 years |
Steven A. Everett | M | - |
University Of Dundee
| 4 years |
Charlotte Deane | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 42 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Hopkins
- Personal Network